Evidence map›Paper›PMID 35103856›Full record

ArticleMedical oncology (Northwood, London, England)2022

RNF144A exerts tumor suppressor function in breast cancer through targeting YY1 for proteasomal degradation to downregulate GMFG expression.

Yin-Ling Zhang, Jin-Ling Cao, Ye Zhang, Li Liao, Ling Deng, Shao-Ying Yang, Shu-Yuan Hu, Yan Ning, Fang-Lin Zhang, Da-Qiang Li

Open access · hybridAbstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Genome-Wide Association Study of Body Conformation Traits in Tashi Goats (Animals : an open access journal from MDPI · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yin-Ling Zhang *Fudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Jin-Ling Cao *Fudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Ye Zhang *Fudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Li LiaoFudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Ling DengFudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Shao-Ying YangFudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Shu-Yuan HuFudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Yan NingDepartment of Pathology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. 1181436196@qq.com.
Fang-Lin ZhangFudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China. zhangfanglin555@sina.com.
Da-Qiang LiFudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism of Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China. daqiangli1974@fudan.edu.cn.ORCID http://orcid.org/0000-0002-5113-2332
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNObstetrics and Gynecology Hospital of Fudan University · CN

Funding

Key Technologies Research and Development Program 2017YFC0908400Key Technologies Research and Development Program 2018YFE0201600National Natural Science Foundation of China 81572584National Natural Science Foundation of China 81772805National Natural Science Foundation of China 82173275
6 · The paper itself

Abstract

Ring finger protein 144A (RNF144A), a poorly characterized member of the RING-in-between-RING family of E3 ubiquitin ligases, is an emerging tumor suppressor, but its underlying mechanism remains largely elusive. To address this issue, we used Affymetrix GeneChip Human Transcriptome Array 2.0 to profile gene expression in MDA-MB-231 cells stably expressing empty vector pCDH and Flag-RNF144A, and found that 128 genes were differentially expressed between pCDH- and RNF144A-expressing cells with fold change over 1.5. We further demonstrated that RNF144A negatively regulated the protein and mRNA levels of glial maturation factor γ (GMFG). Mechanistical investigations revealed that transcription factor YY1 transcriptionally activated GMFG expression, and RNF144A interacted with YY1 and promoted its ubiquitination-dependent degradation, thus blocking YY1-induced GMFG expression. Functional rescue assays showed that ectopic expression of RNF144A suppressed the proliferative, migratory, and invasive potential of breast cancer cells, and the noted effects were partially restored by re-expression of GMFG in RNF144A-overexpressing breast cancer cells. Collectively, these findings reveal that RNF144A negatively regulates GMFG expression by targeting YY1 for proteasomal degradation, thus inhibiting the proliferation, migration, and invasion of breast cancer cells.

Indexed as

Breast NeoplasmsCarrier ProteinsCell Line, TumorCell MovementCell ProliferationDown-RegulationFemaleGlia Maturation FactorHumansRNA, MessengerUbiquitin-Protein LigasesYY1 Transcription FactorCarrier ProteinsGlia Maturation Factorglia maturation factor gammaRNA, MessengerRNF144A protein, humanUbiquitin-Protein LigasesYY1 protein, humanYY1 Transcription FactorBreast cancerGMFGProtein degradationRNF144AYY1

Identifiers

PMID35103856
PMCPMC8807444
OpenAlexW4210579008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.